Jorge Alatorre Alexander, Head of the Oncology Department at National Institute of Respiratory Diseases, shared on LinkedIn:
“It was a privilege to join an outstanding panel of experts to discuss the evolving role of ADCs in lung cancer, with a special focus on patients with HER2-mutant disease and their use in the second-line setting in Cuernavaca.
Our discussion explored the remarkable progress these therapies have achieved, as well as the challenges that remain in optimizing patient selection, expanding access, and integrating these agents into clinical practice.
We also shared perspectives on the future of ADCs from a global standpoint and discussed the unique opportunities and challenges facing Mexico and Latin America as these innovative treatments continue to reshape thoracic oncology.
Thank you to my fellow panelists Kaline Pereira, Jeronimo Rodriguez Cid, Patricia Castillo, Yanin Chávarri for such an engaging and insightful discussion. The future of ADCs in lung cancer is incredibly promising, and continued collaboration will be essential to ensure that more patients benefit from these advances.”
You can also find this interesting:
Adjuvant Icotinib Linked to Better DFS in Resected Stage IA EGFR-Mutant Lung Adenocarcinoma
